EN DE

Mediana Co (041920) Fair Value & Analysis

Healthcare · KR · Market cap 180B KRW

MC Mediana Co 041920 · KQ
Price9,720 KRW
Fair Value6,289 KRW
Upside-35.3%
Quality61/100
Watch Mediana Co for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Highly profitable · 21.9% net margin
Low debt · generates free cash flow
Ranks above peers (8/9)
Wide moat 70/100
Evidence: High Range 4,717 KRW – 7,861 KRW Share as image

Fair value as of: Jul 20, 2026

From 26 valuation models · updated 21 days ago

Share price −5.6% over the past month.

A solid business, but screening 35% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (7,861 KRW). The favourable scenario is already priced in.
  • Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

28,650 KRW 3,733 KRW Fair Value 6,289 KRW Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.

How to read this chart

60‑month range 3,733 KRW – 28,650 KRW · fair‑value band 4,717 KRW – 7,861 KRW · the 9,720 KRW price screens above the 6,289 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Mediana Co (041920) currently trades at 9,720 KRW, while our model-based Fair Value estimate is 6,289 KRW, implying the stock looks roughly 35.3% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Mediana Co generated revenue of 65.0B KRW at a net margin of 21.9%. Revenue grew 59.8% year over year. Fundamentals as of Jul 20, 2026

Our scenario range runs from 4,717 KRW (bear case) to 7,861 KRW (bull case); at 9,720 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 67% below its 52-week high and 100% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -2% fair-value upside, at -35%, 041920 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 4,562 KRW 6,129 KRW 8,401 KRW 80
Residual Income 5,427 KRW 5,320 KRW 4,713 KRW 76
Rev-Margin DCF 4,356 KRW 6,131 KRW 8,202 KRW 74
All 26 models by family
DCF Models
FCF DCF 4,518 KRW 6,307 KRW 9,082 KRW 38
Owner Earnings 5,276 KRW 7,508 KRW 10,970 KRW 31
5Y Revenue Exit 4,356 KRW 6,133 KRW 8,413 KRW 39
5Y EBITDA Exit 4,978 KRW 7,311 KRW 10,054 KRW 41
5Y P/E Exit 5,276 KRW 7,876 KRW 10,635 KRW 38
10Y Revenue Exit 4,294 KRW 5,941 KRW 8,178 KRW 36
10Y EBITDA Exit 4,784 KRW 6,764 KRW 9,444 KRW 37
10Y P/E Exit 4,975 KRW 7,158 KRW 9,893 KRW 35
Earnings-Based
Graham-Dodd 1,944 KRW 6,401 KRW 8,559 KRW 54
Lynch FV 1,441 KRW 2,058 KRW 2,676 KRW 50
PEG = 1.0 1,441 KRW 2,058 KRW 2,676 KRW 46
EPV 3,690 KRW 4,061 KRW 4,387 KRW 59
Dividend Discount
Gordon GGM 198.57 KRW 412.88 KRW 654.99 KRW 70
DDM Multi-Stage 198.57 KRW 336.94 KRW 433.33 KRW 61
Multiples
P/E Multiple 4,717 KRW 6,289 KRW 7,861 KRW 63
P/S Multiple 3,645 KRW 4,860 KRW 6,075 KRW 58
P/B Multiple 3,645 KRW 4,860 KRW 6,075 KRW 55
EV/EBIT 5,572 KRW 6,942 KRW 8,313 KRW 53
EV/EBITDA 5,667 KRW 7,069 KRW 8,472 KRW 54
EV/Revenue 4,395 KRW 5,652 KRW 6,910 KRW 43
Asset-Based
NCAV (Graham) 3,670 KRW 4,918 KRW 7,340 KRW 50
Growth DCF
Growth DCF 4,562 KRW 6,129 KRW 8,401 KRW 80
Rev-Margin DCF 4,356 KRW 6,131 KRW 8,202 KRW 74
Economic Profit
Residual Income 5,427 KRW 5,320 KRW 4,713 KRW 76
ROIC Compounder 3,690 KRW 4,061 KRW 4,387 KRW 72
Growth Earnings
Growth-Adj P/E 3,958 KRW 5,654 KRW 7,350 KRW 68

Widest divergence: DCF Models (6,764 KRW) versus Dividend Discount (336.94 KRW). Highest evidence: Growth DCF (80).

Notify me when 041920 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 65.0B KRW
Revenue growth (YoY) +59.8%
Net margin 21.9%
Return on equity 395%
Free cash flow 4.9B KRW FY2025
Operating margin 15.6%
More key figures
EPS growth (YoY) +202%

Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 61/100

Of which business quality 58 · Market factors (momentum, volatility) 45

Profitability 31
Margins and returns on capital today
Quality Growth 65
Are margins and returns improving?
Cashflow 52
Earnings quality: real cash, not paper profit
Fin. Strength 92
Balance sheet, leverage, solvency risk
Investment 55
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 60
Distance to the 52-week high (market factor)
Net Issuance 56
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Mediana Co.,Ltd, together with its subsidiaries, develops, manufactures, and sells medical devices in South Korea. It offers patient monitors, vital signs monitors, AEDs, monitors/defibrillators, fetal products, body composition analyzers, central monitoring systems, face masks, spot checks and monitors, pulse oximeters, and physio modules.

Full company description

Mediana Co.,Ltd, together with its subsidiaries, develops, manufactures, and sells medical devices in South Korea. It offers patient monitors, vital signs monitors, AEDs, monitors/defibrillators, fetal products, body composition analyzers, central monitoring systems, face masks, spot checks and monitors, pulse oximeters, and physio modules. The company also exports ODM and own branded products through agencies in approximately 80 countries. Mediana Co.,Ltd was founded in 1993 and is headquartered in Wonju-si, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Mediana Co reported revenue of 64.9B KRW in FY2025 versus 56.8B KRW in FY2021, a compound +3.4%/yr. Reported net income was 5.3B KRW in FY2025, compounding −11.9%/yr from FY2021.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
64.9B KRW
Latest YoY
+13.9%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−1.7%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−0.8%
Avg. growth/yr (11Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.9%
Revenue +3.4%/yr
FY21 56.8B KRW
FY22 68.3B KRW
FY23 78.4B KRW
FY24 57.0B KRW
FY25 64.9B KRW
Net income −11.9%/yr
FY21 8.8B KRW
FY22 10.6B KRW
FY23 8.9B KRW
FY24 6.2B KRW
FY25 5.3B KRW

041920 screens 35% overvalued. Compare with InBody Co →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Mediana Co Fair Value". https://www.fairvalue-calculator.com/stock/041920

Peer Group

Health Care · 2227 stocks

How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Healthcare Equipment & Supplies” was too small, so the broader sector is used.)

Quality Score 61 · Above median
Fair Value upside −35% · Below median
Return on equity (TTM) 395% · Top 25%
Return on assets 7% · Top 25%
Net margin (TTM) 22% · Top 25%
Operating margin (TTM) 16% · Above median
Revenue growth 60% · Top 25%

Valuation Multiples vs Health Care median · lower = cheaper

P/FCF 0.0× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 100 · sector 21
PAST 100 · sector 13
HEALTH 100 · sector 96
DIVIDEND 0 · sector 33

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Healthcare Equipment & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).

Stock Price Fair Value vs Fair Value
InBody Co 041830 50,900 KRW 49,984 KRW -2%
i-SENS, Inc 099190 15,270 KRW 8,168 KRW -47%
Value Added Technology Co 043150 16,800 KRW 60,242 KRW +259%
Meta Biomed Co 059210 3,830 KRW 9,875 KRW +158%
Sewoon Medical Co 100700 2,245 KRW 6,054 KRW +170%
MEDIC MEDIC 0.2100 PHP 0.1400 PHP -33%
MEKICS CO., Ltd 058110 1,780 KRW 1,584 KRW -11%
CU Medical Systems, Inc 115480 1,753 KRW 1,134 KRW -35%
PeopleBio, Inc 304840 857.00 KRW 905.70 KRW +6%
Novartis AG NVSN 2,742 MXN 2,379 MXN -13%

Compare Mediana Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Mediana Co (041920) overvalued or undervalued?
As of Jul 20, 2026, our model estimates a fair value of 6,289 KRW versus a price of 9,720 KRW, about −35% (overvalued).
What is the fair value of 041920?
Our model-based fair value for Mediana Co is 6,289 KRW (as of Jul 20, 2026), built from audited fundamentals. The current price is 9,720 KRW.
What is the quality score of 041920?
Mediana Co has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Mediana Co (041920)?
Mediana Co reported trailing-twelve-month revenue of about 65.0B KRW (latest available figure, as of Jul 20, 2026).
What is the net profit margin of 041920?
The net profit margin of Mediana Co is about 21.9%, meaning it keeps roughly 21.9% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Mediana Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.